SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Second quarter summary
Important events second quarter (Apr – Jun 2022)
- On June 1, Abliva’s Board of Directors announced funding of approximately SEK 200 million that is expected to provide the company with the capital required to pursue the Phase 2/3 study with KL1333 to a key interim analysis, as well as prepare NV354 for clinical phase.
- Annual General Meeting was held on May 20, 2022. All proposals were approved, including the re-election of the Board of Directors.
Financial information
April-June 2022*
- Net revenues: SEK 0,000 (18,000)
- Other operating income: SEK 0,000 (0,000)
- Loss before tax: SEK 20,535,000 (30,314,000)
- Loss per share before dilution: SEK 0.04 (0.08)
- Diluted loss per share: SEK 0.04 (0.08)
January-June 2022*
- Net revenues: SEK 0,000 (18,000)
- Other operating income: SEK 0,000 (0,000)
- Loss before tax: SEK 42,564,000 (51,770,000)
- Loss per share before dilution: SEK 0.09 (0.13)
- Diluted loss per share: SEK 0.09 (0.13)
* APM Alternative performance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva’s website www.abliva.com.